Respiratory Diseases Stocks List Ranked for 2024 |

Respiratory Diseases ETFs
Recent Respiratory Diseases News

Symbol	Grade	Name	% Change
SVRA	C	Savara, Inc.	-8.19
REVB	F	Revelation Biosciences, Inc.	-6.36
WINT	F	Windtree Therapeutics, Inc.	-5.53
ALVO	C	Alvotech	-1.69
TBPH	C	Theravance Biopharma, Inc.	-0.95
SPRY	C	ARS Pharmaceuticals, Inc.	-0.68
AZN	A	Astrazeneca PLC	-0.55
SMLR	F	Semler Scientific, Inc.	-0.17
MRK	B	Merck & Company, Inc.	-0.13
VMD	F	Viemed Healthcare, Inc.	0.21

View As Page of Charts

Related ETFs - A few ETFs which own one or more of the above listed Respiratory Diseases stocks.

Symbol	Grade	Name	Weight
PPH	C	Market Vectors Pharmaceutical ETF	12.22
MEDX	D	Horizon Kinetics Medical ETF	10.95
FTXH	D	First Trust Nasdaq Pharmaceuticals ETF	7.55
XLV	C	SPDR Select Sector Fund - Health Care	6.17
IYH	C	iShares U.S. Healthcare ETF	6.03

View all Respiratory Diseases ETFs...

Compare ETFs

Compare FTXH to XLV Compare MEDX to FTXH Compare MEDX to XLV

Respiratory Diseases Stocks Recent News

Date	Stock	Title
Feb 7	VMD	(Exclusive) Stocks To Watch, PRO+ Edition
May 10	REVB	Revelation Biosciences GAAP EPS of -$2.46
May 10	REVB	Revelation Biosciences, Inc. Announces Financial Results for the Three Months Ended March 31, 2024
May 10	AZN	Why Astrazeneca (AZN) is a Top Growth Stock for the Long-Term
May 10	AZN	Catalyst's New CEO Has Big Ideas For The Small Biotech
May 10	MRK	Merck's (NYSE:MRK) investors will be pleased with their notable 90% return over the last three years
May 10	MRK	Merck: The Worst Has Been Avoided (Rating Upgrade)
May 9	SPRY	ARS Pharmaceuticals GAAP EPS of -$0.11
May 9	SVRA	Savara GAAP EPS of -$0.11 misses by $0.01
May 9	SPRY	ARS Pharmaceuticals Highlights neffy Regulatory Progress and Reports First Quarter 2024 Financial Results
May 9	SVRA	Savara Reports First Quarter 2024 Financial Results and Provides Business Update
May 9	MRK	Investors Heavily Search Merck & Co., Inc. (MRK): Here is What You Need to Know
May 9	AZN	Top 5 Health Care Stocks That Could Sink Your Portfolio In Q2
May 9	MRK	Merck says Keytruda failed as first-line therapy for uterine cancer
May 9	MRK	Health Canada Approves KEYTRUDA® for adult patients with locally advanced unresectable or metastatic biliary tract carcinoma, in combination with gemcitabine-based chemotherapy
May 9	MRK	Merck Provides Update on Phase 3 KEYNOTE-B21 Trial Evaluating KEYTRUDA® (pembrolizumab) Plus Chemotherapy, With or Without Radiotherapy, for Patients With Newly Diagnosed, High-Risk Endometrial Cancer After Surgery With Curative Intent
May 9	SMLR	Semler Scientific First Quarter 2024 Earnings: Misses Expectations
May 9	TBPH	Theravance Biopharma to Participate in an Upcoming Investor Conference
May 8	AZN	Update: AstraZeneca, Merck Sue to Protect Lynparza Cancer Drug Patents
May 8	AZN	Every household should be forced to have a smart meter, says British Gas boss

Respiratory Diseases: Respiratory diseases are a group of conditions that affect the lungs and airways. These diseases can range from mild to severe and can include asthma, COPD, pneumonia, and lung cancer. Symptoms of respiratory diseases can include difficulty breathing, coughing, wheezing, and chest pain. Treatment for respiratory diseases can include medications, lifestyle changes, and surgery.

Browse All Tags